Eli Lilly and Company $LLY Shares Sold by Transcend Capital Advisors LLC

Transcend Capital Advisors LLC lessened its stake in shares of Eli Lilly and Company (NYSE:LLY) by 40.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,759 shares of the company’s stock after selling 7,279 shares during the quarter. Transcend Capital Advisors LLC’s holdings in Eli Lilly and Company were worth $8,387,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Lazard Freres Gestion S.A.S. grew its position in Eli Lilly and Company by 114.3% in the second quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock worth $60,253,000 after buying an additional 41,222 shares during the last quarter. Precedent Wealth Partners LLC grew its position in Eli Lilly and Company by 15.3% in the second quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock worth $229,000 after buying an additional 39 shares during the last quarter. Capital Advisors Inc. OK grew its position in Eli Lilly and Company by 6.8% in the second quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock worth $5,260,000 after buying an additional 429 shares during the last quarter. Family CFO Inc acquired a new position in Eli Lilly and Company in the second quarter worth approximately $54,000. Finally, Duquesne Family Office LLC grew its position in Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after buying an additional 32,640 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.6%

Shares of NYSE:LLY opened at $825.86 on Monday. The firm has a fifty day moving average of $768.01 and a two-hundred day moving average of $768.56. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $935.63. The firm has a market capitalization of $781.65 billion, a P/E ratio of 53.98, a price-to-earnings-growth ratio of 1.23 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. Eli Lilly and Company’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period in the prior year, the business posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, equities analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

LLY has been the topic of several recent research reports. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price target on the stock. in a research report on Sunday, August 17th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Tuesday, October 14th. Cantor Fitzgerald set a $925.00 target price on Eli Lilly and Company and gave the company an “overweight” rating in a report on Thursday, October 9th. Weiss Ratings restated a “hold (c+)” rating on shares of Eli Lilly and Company in a report on Friday. Finally, Guggenheim restated a “buy” rating and issued a $948.00 target price on shares of Eli Lilly and Company in a report on Thursday, October 16th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $938.61.

Insider Activity

In other news, Director J Erik Fyrwald acquired 1,565 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the transaction, the director owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Gabrielle Sulzberger acquired 117 shares of Eli Lilly and Company stock in a transaction that occurred on Tuesday, August 12th. The shares were purchased at an average cost of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. The trade was a 4.52% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 4,514 shares of company stock valued at $2,894,841. 0.14% of the stock is currently owned by company insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.